COMP <GO>
NUS vs ABBV // RETURN ON INVESTED CAPITAL (ROIC)
Nu Skin Enterprises Inc. (NYSE) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: NUS 3
— ABBV 7
▲ RETURN ON INVESTED CAPITAL (ROIC) LEADER: ABBV
LAST: $4.69 (-1.47%) • MKT CAP: $228.3M
roic
6.70%
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
roic
29.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (NUS VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | NUS | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.40% | 70.20% | -0.80 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) ACTIVE | 6.70% | 29.00% | -22.30 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 33.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 20.15% | 3.47% | +16.68 | NUS | /fcf-yield <GO> |
| Operating Margin | 4.40% | 24.60% | -20.20 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 10.80% | 6.90% | +3.90 | NUS | /net-margins <GO> |
| Revenue Growth (YoY) | -14.30% | 8.60% | -22.90 | ABBV | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 5.18% | 2.27% | +2.91 | NUS | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 3.54 | 5.33 | -1.79 | ABBV | /balance-sheet <GO> |
| Piotroski F-Score Quality | 7/9 | 7/9 | 0.00 | TIE | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 43.2 | 65.1 | -21.94 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 113.1x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $228.3M | $513.86B | -$513.63B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | NUS REV | ABBV REV | NUS GROSS % | ABBV GROSS % | NUS FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $1.49B | $61.16B | 69.4% | 70.2% | $46.0M | $17.82B |
| FY 2024 | $1.73B | $56.33B | 68.2% | 70.0% | $70.2M | $17.83B |
| FY 2023 | $1.97B | $54.32B | — | — | $118.6M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
NUS // BETA —
ABBV // BETA 1.15